Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.17 Million USD | 70.74% |
| 2022 | -10.8 Million USD | 59.19% |
| 2021 | -26.46 Million USD | -58.11% |
| 2020 | -16.74 Million USD | 3.17% |
| 2019 | -17.28 Million USD | 13.92% |
| 2018 | -20.08 Million USD | -230.02% |
| 2017 | -6.08 Million USD | -51.6% |
| 2016 | -4.01 Million USD | 20.04% |
| 2015 | -5.02 Million USD | 51.66% |
| 2014 | -10.38 Million USD | 35.95% |
| 2013 | -16.21 Million USD | -64.13% |
| 2012 | -9.87 Million USD | -233.82% |
| 2011 | 7.38 Million USD | 22335.0% |
| 2010 | -33.19 Thousand USD | 87.55% |
| 2009 | -266.58 Thousand USD | 76.58% |
| 2008 | -1.13 Million USD | -139.37% |
| 2007 | -475.5 Thousand USD | 32.77% |
| 2006 | -707.27 Thousand USD | 24.58% |
| 2005 | -937.78 Thousand USD | 74.42% |
| 2004 | -3.66 Million USD | -2.3% |
| 2003 | -3.58 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.94 Million USD | 38.46% |
| 2024 Q2 | -1.34 Million USD | 30.67% |
| 2023 Q4 | -3.16 Million USD | 39.78% |
| 2023 FY | -3.16 Million USD | 70.74% |
| 2023 Q1 | -8.74 Million USD | 19.06% |
| 2023 Q2 | -6.21 Million USD | 28.89% |
| 2023 Q3 | -5.24 Million USD | 15.58% |
| 2022 Q1 | -20.8 Million USD | 21.4% |
| 2022 Q3 | -13.11 Million USD | 24.9% |
| 2022 FY | -10.8 Million USD | 59.19% |
| 2022 Q4 | -10.8 Million USD | 17.66% |
| 2022 Q2 | -17.46 Million USD | 16.03% |
| 2021 Q4 | -26.46 Million USD | 8.5% |
| 2021 FY | -26.46 Million USD | -58.11% |
| 2021 Q3 | -28.92 Million USD | 14.9% |
| 2021 Q2 | -33.99 Million USD | 4.94% |
| 2021 Q1 | -35.75 Million USD | -113.6% |
| 2020 Q4 | -16.74 Million USD | -88.98% |
| 2020 FY | -16.74 Million USD | 3.17% |
| 2020 Q3 | -8.85 Million USD | -1.33% |
| 2020 Q2 | -8.74 Million USD | 35.27% |
| 2020 Q1 | -13.5 Million USD | 21.88% |
| 2019 FY | -17.28 Million USD | 13.92% |
| 2019 Q1 | -29.13 Million USD | -45.08% |
| 2019 Q2 | -24.95 Million USD | 14.37% |
| 2019 Q3 | -21.35 Million USD | 14.42% |
| 2019 Q4 | -17.28 Million USD | 19.04% |
| 2018 Q4 | -20.08 Million USD | -47.45% |
| 2018 Q2 | -3.91 Million USD | 16.43% |
| 2018 Q1 | -4.69 Million USD | 22.93% |
| 2018 FY | -20.08 Million USD | -230.02% |
| 2018 Q3 | -13.62 Million USD | -247.51% |
| 2017 Q2 | 333.63 Thousand USD | 115.79% |
| 2017 FY | -6.08 Million USD | -51.6% |
| 2017 Q4 | -6.08 Million USD | -1439.18% |
| 2017 Q3 | -395.38 Thousand USD | -218.51% |
| 2017 Q1 | -2.11 Million USD | 47.38% |
| 2016 Q4 | -4.01 Million USD | 19.79% |
| 2016 FY | -4.01 Million USD | 20.04% |
| 2016 Q1 | -3.28 Million USD | 34.49% |
| 2016 Q2 | -5.42 Million USD | -64.88% |
| 2016 Q3 | -5 Million USD | 7.7% |
| 2015 Q2 | -8 Million USD | 10.76% |
| 2015 FY | -5.02 Million USD | 51.66% |
| 2015 Q4 | -5.02 Million USD | -208.12% |
| 2015 Q3 | -1.62 Million USD | 79.66% |
| 2015 Q1 | -8.97 Million USD | 13.58% |
| 2014 Q1 | -14.55 Million USD | 10.2% |
| 2014 Q2 | -12.86 Million USD | 11.65% |
| 2014 FY | -10.38 Million USD | 35.95% |
| 2014 Q4 | -10.38 Million USD | 10.91% |
| 2014 Q3 | -11.65 Million USD | 9.39% |
| 2013 FY | -16.21 Million USD | -64.13% |
| 2013 Q4 | -16.21 Million USD | -98.69% |
| 2013 Q3 | -8.15 Million USD | -31.07% |
| 2013 Q1 | -8.28 Million USD | 16.15% |
| 2013 Q2 | -6.22 Million USD | 24.84% |
| 2012 Q4 | -9.87 Million USD | 15.35% |
| 2012 Q2 | 960.83 Thousand USD | 884.6% |
| 2012 Q1 | -122.46 Thousand USD | -101.66% |
| 2012 FY | -9.87 Million USD | -233.82% |
| 2012 Q3 | -11.66 Million USD | -1314.49% |
| 2011 Q2 | 4.56 Million USD | 49.57% |
| 2011 FY | 7.38 Million USD | 22335.0% |
| 2011 Q1 | 3.05 Million USD | 9295.22% |
| 2011 Q3 | 6.1 Million USD | 33.7% |
| 2011 Q4 | 7.38 Million USD | 20.92% |
| 2010 Q1 | -399.54 Thousand USD | -49.88% |
| 2010 FY | -33.19 Thousand USD | 87.55% |
| 2010 Q4 | -33.19 Thousand USD | 90.42% |
| 2010 Q3 | -346.44 Thousand USD | -142.58% |
| 2010 Q2 | 813.63 Thousand USD | 303.64% |
| 2009 Q4 | -266.58 Thousand USD | 59.18% |
| 2009 FY | -266.58 Thousand USD | 76.58% |
| 2009 Q1 | -3223.00 USD | 99.72% |
| 2009 Q2 | -1.68 Million USD | -52268.41% |
| 2009 Q3 | -653.02 Thousand USD | 61.31% |
| 2008 Q2 | -3.56 Million USD | -81.25% |
| 2008 FY | -1.13 Million USD | -139.37% |
| 2008 Q4 | -1.13 Million USD | 57.0% |
| 2008 Q3 | -2.64 Million USD | 25.75% |
| 2008 Q1 | -1.96 Million USD | -313.64% |
| 2007 Q4 | -475.5 Thousand USD | 49.18% |
| 2007 FY | -475.5 Thousand USD | 32.77% |
| 2007 Q2 | -151.46 Thousand USD | 79.8% |
| 2007 Q1 | -749.73 Thousand USD | -6.0% |
| 2007 Q3 | -935.67 Thousand USD | -517.73% |
| 2006 Q2 | -861.68 Thousand USD | -18.77% |
| 2006 Q1 | -725.53 Thousand USD | 22.63% |
| 2006 FY | -707.27 Thousand USD | 24.58% |
| 2006 Q4 | -707.27 Thousand USD | -50.48% |
| 2006 Q3 | -470.01 Thousand USD | 45.45% |
| 2005 Q3 | -330.2 Thousand USD | 70.36% |
| 2005 Q4 | -937.78 Thousand USD | -184.01% |
| 2005 Q2 | -1.11 Million USD | 38.96% |
| 2005 FY | -937.78 Thousand USD | 74.42% |
| 2005 Q1 | -1.82 Million USD | 50.22% |
| 2004 Q3 | -4.31 Million USD | 16.17% |
| 2004 FY | -3.66 Million USD | -2.3% |
| 2004 Q1 | -6.01 Million USD | -67.77% |
| 2004 Q2 | -5.14 Million USD | 14.4% |
| 2004 Q4 | -3.66 Million USD | 15.02% |
| 2003 Q4 | -3.58 Million USD | -122.91% |
| 2003 Q2 | -1.78 Million USD | 0.0% |
| 2003 FY | -3.58 Million USD | 0.0% |
| 2003 Q3 | -1.6 Million USD | 9.83% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 35.866% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 16.886% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 102.968% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 95.748% |
| Azitra, Inc. | -910.04 Thousand USD | -248.423% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 25.182% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 370.478% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 161.13% |
| CEL-SCI Corporation | 9.42 Million USD | 133.639% |
| iBio, Inc. | -9.75 Million USD | 67.479% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 90.241% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 55.657% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -147.525% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 823.193% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -713.025% |
| NanoViricides, Inc. | -4.79 Million USD | 33.911% |
| BiomX Inc. | -772 Thousand USD | -310.725% |
| BiomX Inc. | -772 Thousand USD | -310.725% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 219.788% |
| Palatin Technologies, Inc. | -8.93 Million USD | 64.521% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 122.882% |